HAI + folinic acid + 5-fluorouracil + oxaliplatin

HAI + folinic acid + 5-fluorouracil + oxaliplatin is an investigational chemotherapy regimen, also known as HAI FOLFOX, developed by Western Regional Medical Center for the treatment of liver-predominant metastatic breast cancer. This regimen utilizes hepatic arterial infusion (HAI) to deliver a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (leucovorin) directly to the liver via the hepatic artery. This targeted delivery approach is designed to maximize the concentration of cytotoxic agents at the site of hepatic metastases while minimizing systemic exposure and associated side effects. Oxaliplatin acts as a platinum-based antineoplastic agent that induces DNA cross-linking, thereby inhibiting DNA replication and transcription. 5-fluorouracil is a pyrimidine analog that, when combined with folinic acid, potently inhibits thymidylate synthase, an essential enzyme for DNA synthesis. The regimen was evaluated in a pilot clinical trial (NCT01937507) for patients who had failed prior systemic therapies.

Other names

HAI-FOLFOXHepatic Arterial Infusion of FOLFOX